Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes

Toxicology Letters

Volumn 102-103, Issue , 1998, Pages 143-147

  Daly, Ann K ^a   Fairbrother, Karen S ^a   Smart, Joanne ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Ah receptor; CYP1A1; CYP2E1; Cytochrome P450; Genetic polymorphism

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450; DIMETHYLNITROSAMINE DEMETHYLASE; ETHOXYRESORUFIN DEETHYLASE;

ARTICLE; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

ANIMALS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2E1; HUMANS; POLYMORPHISM, GENETIC;

EID: 0032437084     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(98)00299-9     Document Type: Article

References (24)

1. Ayesh, R., Idle, J.R., Ritchie, J.C., Crothers, M.J., Hetzel, M.R., 1984. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 311, 169-170.
2. Caporaso, N.E., Tucker, M.A., Hoover, R.N., 1990. Lung cancer and the debrisoquine metabolic phenotype. J. Natl. Cancer Inst. 82, 1264-1272.
3. Catteau, A., Douriez, E., Beaune, P., Poisson, N., Bonaiti-Pellie, C., Laurent, P., 1995. Genetic polymorphism of induction of CYP1A1 (EROD) activity. Pharmacogenetics 5, 110-119.
4. Daly, A.K., 1995. Molecular basis of polymorphic drug metabolism. J. Mol. Med. 73, 539-553.
5. Daly, A.K., Steen, V.M., Fairbrother, K.S., Idle, J.R., 1996. CYP2D6 multiallelism. Methods Enzymol. 272, 199-210.
6. Fairbrother, K.S., Grove, J., de Waziers, I., Steimel, D.T., Day, C.P., Crespi, C.L., Daly, A.K., 1998. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics (in press).
7. Gonzalez, F.J., Idle, J.R., 1994. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin. Pharmacokinet. 26, 59-70.
8. Hayashi, S., Watanabe, J., Kawajiri, K., 1991. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J. Biochem. 110, 559-565.
9. Hayashi, S.-I., Watanabe, J., Kawajiri, K., 1992. High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501A1 and mu-class glutathione S-transferase genes. Jpn. J. Cancer Res. 83, 866-870.
10. Hirvonen, A., Husgafvel-Pursiainen, K., Anttila, S., Karjalainen, A., Sorsa, M., Vainio, H., 1990. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics 2, 259-263.
11. Jaiswal, A.K., Gonzalez, F.J., Nebert, D.W., 1985. Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism. Nucl. Acids Res. 13, 4503-4520.
12. Kawajiri, K., Watanabe, J., Eguchi, H., Nakachi, K., Kiyohara, C., Hayashi, S., 1995. Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics 5, 151-158.
13. Kellermann, G., Shaw, C.R., Luyten-Kellermann, M., 1973a. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. New Engl. J. Med. 289, 934-937.
14. Kellermann, G., Luyten-Kellermann, M., Shaw, C.R., 1973b. Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. Am. J. Hum. Genet. 25, 327-331.
15. Ko, H.P., Okino, S.T., Ma, Q., Whitlock, J.P., 1997. Transactivation domains facilitate promoter occupancy for the dioxin-inducible CYP1A1 gene in vivo. Mol. Cell Biol. 17, 3497-3507.
16. Kouri, R.E., McKinney, C.E., Slomiany, D.J., Snodgrass, D.R., Wray, N.P., McLemore, T.L., 1982. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analysed in cryopreserved lymphocytes. Cancer Res. 42, 5030-5037.
17. London, S.J., Daly, A.K., Leathart, J.B.S., Navidi, W.C., Carpenter, C.C., Idle, J.R., 1997. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis 18, 1203-1214.
18. Nebert, D.W., Gielen, J.E., 1972. Genetic regulation of aryl hydrocarbon hydroxylase induction in the mouse. Fed. Proc. 31, 1315-1325.
19. Nebert, D.W., Ingelman-Sundberg, M., Daly, A.K., 1998. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing (DME) genes, their functional importance, and nomenclature issues. Drug Metab. Rev. (in press).
20. Paigen, B., Gurtoo, H.L., Minowada, J., 1977. Questionable relation of aryl hydrocarbon hydroxylase to lung cancer risk. New Engl. J. Med. 297, 346-350.
21. Prasad, R., Prasad, N., Harrell, J.E., 1979. Aryl hydrocarbon hydroxylase inducibility and lymphoblast formation in lung cancer patients. Int. J. Cancer 23, 316-320.
22. Stucker, I., Cosme, J., Laurent, P., 1995. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure. Carcinogenesis 16, 2759-2764.
23. Vaury, C., Laine, R., Noguiez, P., 1995. Human glutathione S-transferase is associated with a high inducibility of cytochrome P450 1A1 gene transcription. Cancer Res. 55, 5520-5523.
24. Wolf, C.R., Smith, C.A.D., Gough, A.C., 1992. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 13, 1035-1038.